Hugo Maas

2.4k total citations · 1 hit paper
22 papers, 1.7k citations indexed

About

Hugo Maas is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Hematology. According to data from OpenAlex, Hugo Maas has authored 22 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cardiology and Cardiovascular Medicine, 6 papers in Molecular Biology and 5 papers in Hematology. Recurrent topics in Hugo Maas's work include Atrial Fibrillation Management and Outcomes (5 papers), Cardiac Arrhythmias and Treatments (4 papers) and Blood Coagulation and Thrombosis Mechanisms (4 papers). Hugo Maas is often cited by papers focused on Atrial Fibrillation Management and Outcomes (5 papers), Cardiac Arrhythmias and Treatments (4 papers) and Blood Coagulation and Thrombosis Mechanisms (4 papers). Hugo Maas collaborates with scholars based in Germany, United Kingdom and Netherlands. Hugo Maas's co-authors include Mats O. Karlsson, Lena E. Friberg, Laurent Nguyen, Anja Henningsson, Martina Brueckmann, Ruth Harper, Michael J. Mack, Maximilian T. Lobmeyer, Stuart J. Connolly and Yasser Khder and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Hugo Maas

22 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

2013 948 citations John W. Eikelboom, Stuart J. Connolly et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Hugo Maas

Since Specialization

Citations

This map shows the geographic impact of Hugo Maas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugo Maas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugo Maas more than expected).

Fields of papers citing papers by Hugo Maas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hugo Maas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugo Maas. The network helps show where Hugo Maas may publish in the future.

Co-authorship network of co-authors of Hugo Maas

This figure shows the co-authorship network connecting the top 25 collaborators of Hugo Maas. A scholar is included among the top collaborators of Hugo Maas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hugo Maas. Hugo Maas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An introduction to causal inference for pharmacometricians 2022 ·CPT Pharmacometrics & Systems Pharmacology ·James A. Rogers, Hugo Maas, (unknown)	11
2	A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients 2019 ·Clinical Pharmacokinetics ·(unknown), Hugo Maas, (unknown), Nina Hanke, (unknown), Thorsten Lehr	19
3	Modeling Exposure‐Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib 2019 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Hugo Maas, Alexander Staab, Matthias Freiwald, Mats O. Karlsson	6
4	Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function 2018 ·Journal of Cardiovascular Pharmacology and Therapeutics ·Jack L. Martin, (unknown), Raymond C. Manuel, (unknown), Sabrina Wiebe, Hugo Maas	13
5	Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials 2018 ·Thrombosis and Haemostasis ·Hugo Maas, Savion Gropper, Fenglei Huang, Joachim Stangier, Igor Tartakovsky, Martina Brueckmann, (unknown), Lesley Mitchell	15
6	Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism 2017 ·Thrombosis and Haemostasis ·(unknown), (unknown), Ruth Harper, Fenglei Huang, Martina Brueckmann, Savion Gropper, Hugo Maas, Igor Tartakovsky, Ildar Nurmeev, Lesley Mitchell, Leonardo R. Brandão, Elizabeth Chalmers, Manuela Albisetti	27
7	Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability 2017 ·Journal of Thrombosis and Haemostasis ·(unknown), Manuela Albisetti, Branislav Biss, Lisa Bomgaars, Martina Brueckmann, Savion Gropper, Ruth Harper, Fenglei Huang, Matteo Luciani, Hugo Maas, Igor Tartakovsky, Lesley Mitchell	31
8	Pharmacokinetics (PK) and Pharmacodynamics (PD), Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Etexilate Given after Standard Anticoagulant Therapy in Children from Birth to Less Than One Year Old, with Venous Thromboembolism 2016 ·Blood ·(unknown), (unknown), Ruth Harper, Fenglei Huang, Martina Brueckmann, Savion Gropper, Hugo Maas, Igor Tartakovsky, Ildar Nurmeev, Lesley Mitchell, Leonardo R. Brandão, Manuela Albisetti	3
9	Generating Virtual Patients by Multivariate and Discrete Re-Sampling Techniques 2015 ·Pharmaceutical Research ·Donato Teutonico, Flora T. Musuamba, Hugo Maas, (unknown), Shuying Yang, Meindert Danhof, Oscar Della Pasqua	31
10	Prediction of Disease Progression, Treatment Response and Dropout in Chronic Obstructive Pulmonary Disease (COPD) 2014 ·Pharmaceutical Research ·Flora T. Musuamba, Donato Teutonico, Hugo Maas, (unknown), Shuying Yang, Meindert Danhof, Oscar Della Pasqua	10
11	Dabigatran versus Warfarin in Patients with Mechanical Heart Valves breakdown → 2013 ·New England Journal of Medicine ·John W. Eikelboom, Stuart J. Connolly, Martina Brueckmann, Christopher B. Granger, A. Pieter Kappetein, Michael J. Mack, Jon Blatchford, (unknown), Jeffrey Friedman, (unknown), Ruth Harper, Yasser Khder, Maximilian T. Lobmeyer, Hugo Maas, Jens‐Uwe Voigt, Maarten L. Simoons, Frans Van de Werf	948
12	Relevance of Absorption Rate and Lag Time to??the Onset of Action in Migraine 2008 ·Clinical Pharmacokinetics ·Hugo Maas, (unknown), Meindert Danhof, Oscar Della Pasqua	6
13	Analysis of responses in migraine modelling using hidden Markov models 2007 ·Statistics in Medicine ·Vladimir V. Anisimov, Hugo Maas, Meindert Danhof, Oscar Della Pasqua	7
14	A model‐based approach to treatment comparison in acute migraine 2006 ·British Journal of Clinical Pharmacology ·Hugo Maas, Meindert Danhof, Oscar Della Pasqua	8
15	Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment 2004 ·Journal of Controlled Release ·(unknown), (unknown), Tamara J. van Steeg, Hendrik van den Bussche, Hugo Maas, (unknown), Meindert Danhof, Joke A. Bouwstra, Teus van Laar	25
16	A Competitive Interaction Model Predicts the Effect of WAY-100,635 on the Time Course of R -(+)-8-Hydroxy-2-(di-n-propylamino)tetralin-Induced Hypothermia 2002 ·Journal of Pharmacology and Experimental Therapeutics ·Klaas P. Zuideveld, (unknown), Hugo Maas, J. M. Gubbens‐Stibbe, L. A. Peletier, Piet H. van der Graaf, Meindert Danhof	30
17	Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats 2002 ·Journal of Pharmacology and Experimental Therapeutics ·Klaas P. Zuideveld, (unknown), Hugo Maas, L. A. Peletier, Piet H. van der Graaf, Meindert Danhof	26
18	Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs 2002 ·Journal of Clinical Oncology ·Lena E. Friberg, Anja Henningsson, Hugo Maas, Laurent Nguyen, Mats O. Karlsson	408
19	A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia 2001 ·American Journal of Physiology-Regulatory, Integrative and Comparative Physiology ·Klaas P. Zuideveld, Hugo Maas, (unknown), (unknown), Piet H. van der Graaf, L. A. Peletier, Meindert Danhof	42
20	[Electrophoretic studies on the serum of loirs (Glis glis) after irradiation and in hibernation]. 1957 ·PubMed ·G Schubert, (unknown), Hugo Maas	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact